VXRT Vaxart

Vaxart, Inc. to Participate in September Virtual Investor Conferences

Vaxart, Inc. to Participate in September Virtual Investor Conferences

- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th – 16th

- Sachs Associates: 20th Annual Biotech in Europe Forum - September 21st – 24th

- SVB Leerink: CybeRx Series: Vaccine Forum - September 23rd & – 24th

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced senior management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

H.C. Wainwright: 22nd Annual Global Investment Conference

Title:Vaxart, Inc. (VXRT) Company Presentation / Fireside Chat
Date:Monday, September 14th 2020
Time:10:30 am Eastern Time
Presenter:Andrei Floroiu, President & CEO
  
Sachs Associates: 20th Annual Biotech in Europe Forum
Title (1):Pandemic Response Day: Vaccine Panel
Date:Monday, September 21st 2020
Time:13:05 -14:00 Central European Time
Panelists:Andrei Floroiu, President & CEO Vaxart, Inc.

 Andrew Allen, Co-Founder, President & CEO, Gritstone Oncology
 Frederic Ors, CEO, IMV, Inc.
 Johan Van Hoof, Global Therapeutic Area Head, IDV Vaccines, Johnson & Johnson
  
Title (2):Spotlight Showcase Vaxart, Inc. (VXRT) Company Presentation
Date:Monday, September 21st 2020
Time:14:05 -14:25 Central European Time
Presenter:Andrei Floroiu, President & CEO Vaxart, Inc.
  
SVB LEERINK: CybeRx Series – Vaccine Forum
Title:Vaxart, Inc. (VXRT) - Fireside Chat
Date:Wednesday, September 23rd 2020
Time:2:00 am Eastern Time
Presenters:Andrei Floroiu, President & CEO
 Sean Tucker, Ph.D., Founder & Chief Scientific Officer

Webcast Links

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Company’s website.

About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet vaccine is easier to distribute, store and administer than injectable vaccines and may provide significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit

Contacts

Investors:

Joyce Allaire

LifeSci Advisors



617.435.6602

Media:

Gloria Gasaatura

LifeSci Communications



646.970.4688

EN
03/09/2020

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Scien...

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026. Presentation Details: Date and Time: Wednesday, February 25 at 4:00pm ETRegistration and Webcast: ...

February 18, 2026 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candida...

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population SOUTH SAN FRANCISCO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”...

January 15, 2026 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Participate in the Global BioInnovation Forum on January 13,...

Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will participate in the Global BioInnovation Forum, a virtual gathering of senior leaders building and scaling next-generation life science and health innovation companies. Presentation Details: Speakers: Steven Lo, Chief Executive Officer, Sean T...

January 8, 2026 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Provides Business Update and Reports Third Quarter 2025 Financi...

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus va...

November 13, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Upcoming Conference Calls

Vaxart to Host Upcoming Conference Calls Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced it will host two upcoming webcast conference calls. Third Quarter 2025 Financial ResultsVaxart will provide a business update and report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 13, 2025. The Vaxart senior mana...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch